The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis.
This study compared the long-term effects of the levonorgestrel-releasing intrauterine device with those of GnRH agonist administration on serum levels of CA-125 in patients with endometriosis. The levonorgestrel-releasing intrauterine device was found to be as efficient as GnRH agonist in reducing CA-125 serum levels.
de Sá Rosa e Silva
Ana Carolina Japur
AC
Department of Obstetrics and Gynecology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil. anasars@convex.com.br
Rosa e Silva
Júlio Cesar
JC
Nogueira
Antônio Alberto
AA
Petta
Carlos Alberto
CA
Abrão
Maurício Simões
MS
Ferriani
Rui Alberto
RA
D000293:Adolescent; D000328:Adult; D018394:CA-125 Antigen / Q000097:blood*; D003271:Contraceptive Agents, Female / Q000008:administration & dosage; D004715:Endometriosis / Q000097:blood* / Q000188:drug therapy*; D019544:Equipment Failure Analysis; D005260:Female; D006801:Humans; D007436:Intrauterine Devices, Medicated; D016912:Levonorgestrel / Q000008:administration & dosage*; D016896:Treatment Outcome
D018394:CA-125 Antigen; D003271:Contraceptive Agents, Female; D016912:Levonorgestrel